Immunosuppression in relapsing remitting multiple sclerosis: moving towards personalized treatment

References

• Reich DS, Lucchinetti CF, Calabresi PA. Multiple Sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Solaro C, Ponzio M, Moran E, et al. The changing face of multiple sclerosis: prevalence and incidence in an aging population. Mult Scler. 2015;21(10):1244–1250.
   PubMed Web of Science ®Google Scholar
• Wingerchuk DM, Weinshenker BG. Disease modifying therapies for relapsing multiple sclerosis. BMJ (Clin Res Ed). 2016;354:i3518.
   PubMed Web of Science ®Google Scholar
• Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med. 2017;376(3):209–220.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Kern R, Thomas K. Multiple sclerosis: clinical profiling and data collection as prerequisite for personalized medicine approach. BMC Neurol. 2016;16:124.
   PubMed Web of Science ®Google Scholar
• Vargas DL, Tyor WR. Update on disease-modifying therapies for multiple sclerosis. J Invest Med. 2017;65(5):883–891.
   PubMed Web of Science ®Google Scholar
• Ziemssen T, Thomas K. Treatment optimization in multiple sclerosis: how do we apply emerging evidence? Expert Rev Clin Immunol. 2017;13(6):509–511.
   PubMed Web of Science ®Google Scholar
• Rotstein D, Montalban X. Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis. Nat Rev Neurol. 2019;15:287–300.
   PubMed Web of Science ®Google Scholar
• Solaro C, Trabucco E, Signori A, et al. Depressive Symptoms correlate with disability and disease course in multiple sclerosis patients: an Italian multi-center study using the beck depression inventory. PloS One. 2016;11(9):e0160261.
   PubMed Web of Science ®Google Scholar
• Moss BP, Rensel MR, Hersh CM. Wellness and the role of comorbidities in multiple sclerosis. Neurotherapeutics. 2017;14(4):999–1017.
   PubMed Web of Science ®Google Scholar
• Cerqueira JJ, Compston DAS, Geraldes R, et al. Time matters in multiple sclerosis: can early treatment and long-term follow-up ensure everyone benefits from the latest advances in multiple sclerosis? J Neurol Neurosurg Psychiatry. 2018;89(8):844–850.
   PubMed Web of Science ®Google Scholar
• Lunde HMB, Assmus J, Myhr KM, et al. Survival and cause of death in multiple sclerosis: a 60-year longitudinal population study. J Neurol Neurosurg Psychiatry. 2017;88(8):621–625.
   PubMed Web of Science ®Google Scholar
• Tortorella C, Ruggieri M, Di Monte E, et al. Serum and CSF N-acetyl aspartate levels differ in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry. 2011;82(12):1355–1359.
   PubMed Web of Science ®Google Scholar
• Paul A, Comabella M, Gandhi R. Biomarkers in multiple sclerosis. Cold Spring Harb Perspect Med. 2019;9:3.
   Web of Science ®Google Scholar
• Housley WJ, Pitt D, Hafler DA. Biomarkers in multiple sclerosis. Clin Immunol. 2015;161(1):51–58.
   PubMed Web of Science ®Google Scholar
• Harris VK, Sadiq SA. Biomarkers of therapeutic response in multiple sclerosis: current status. Mol Diagn Ther. 2014;18(6):605–617.
   PubMed Web of Science ®Google Scholar
• Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol Sci. 2008;29(Suppl 2):S253–5.
   PubMed Web of Science ®Google Scholar
• Edan G, Le Page E. Induction therapy for patients with multiple sclerosis: why? When? How? CNS Drugs. 2013;27(6):403–409.
   PubMed Web of Science ®Google Scholar
• Rieckmann P. Concepts of induction and escalation therapy in multiple sclerosis. J Neurol Sci. 2009;277(Suppl 1):S42–5.
   PubMedGoogle Scholar
• D’Amico E, Ziemssen T, Cottone S. Induction therapy for the management of early relapsing forms of multiple sclerosis. A critical opinion. Exp Opin Pharmacother. 2017;18(15):1553–1556.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: http://www.prisma-statement.org/
   Google Scholar
• [cited 2019 Jul]. Available from: https://www.neurology.org/ … /level_of_evidence_classification
   Google Scholar
• Parnell GP, Booth DR. The multiple sclerosis (MS) genetic risk factors indicate both acquired and innate immune cell subsets contribute to MS pathogenesis and identify novel therapeutic opportunities. Front Immunol. 8(425):2017.
   PubMedGoogle Scholar
• Leray E, Yaouanq J, Le Page E, et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain. 2010;133(Pt 7):1900–1913.
   PubMedGoogle Scholar
• Sumowski JF, Rocca MA, Leavitt VM, et al. Brain reserve and cognitive reserve in multiple sclerosis: what you’ve got and how you use it. Neurology. 2013; 81(6):604.
   Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178.
   PubMed Web of Science ®Google Scholar
• van den Broek M, Lems WF, Allaart CF. BeSt practice: the success of early-targeted treatment in rheumatoid arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S35–8.
   PubMed Web of Science ®Google Scholar
• Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol. 2015;15(9):545–558.
   PubMed Web of Science ®Google Scholar
• Weiner HL, Cohen JA. Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunologic effects. Mult Scler. 2002;8(2):142–154.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Leone C, Zanghi A, et al. Lateral and escalation therapy in relapsing-remitting multiple sclerosis: a comparative study. J Neurol. 2016;263(9):1802–1809.
   PubMed Web of Science ®Google Scholar
• Kalincik T, Manouchehrinia A, Sobisek L, et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain. 2017;140(9):2426–2443.
   PubMedGoogle Scholar
• Klotz L, Havla J, Schwab N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord. 2019;12:1756286419836571.
   Web of Science ®Google Scholar
• Menon S, Shirani A, Zhao Y, et al. Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2013;84(11):1192–1198.
   PubMed Web of Science ®Google Scholar
• Rush CA, MacLean HJ, Freedman MS. Aggressive multiple sclerosis: proposed definition and treatment algorithm. Nat Rev Neurol. 2015;11(7):379–389.
   PubMed Web of Science ®Google Scholar
• Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain. 2010;133(Pt 7):1914–1929.
   PubMed Web of Science ®Google Scholar
• Casetta I, Iuliano G, Filippini G. Azathioprine for multiple sclerosis. J Neurol Neurosurg. 2009;80(2):131.
   PubMed Web of Science ®Google Scholar
• Goodin DS, Frohman EM, Garmany GP Jr., et al. Disease modifying therapies in multiple sclerosis: report of the therapeutics and technology assessment subcommittee of the American academy of neurology and the MS council for clinical practice guidelines. Neurology. 2002;58(2):169–178.
   PubMed Web of Science ®Google Scholar
• Markovic-Plese S, Bielekova B, Kadom N, et al. Longitudinal MRI study: the effects of azathioprine in MS patients refractory to interferon beta-1b. Neurology. 2003;60(11):1849–1851.
   PubMed Web of Science ®Google Scholar
• Patti F, Nicoletti A, Pappalardo A, et al. Frequency and severity of headache is worsened by Interferon-beta therapy in patients with multiple sclerosis. Acta Neurol Scand. 2012;125(2):91–95.
   PubMed Web of Science ®Google Scholar
• Talar-Williams C, Hijazi YM, Walther MM, et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med. 1996;124(5):477–484.
   PubMed Web of Science ®Google Scholar
• Auricchio F, Scavone C, Cimmaruta D, et al. Drugs approved for the treatment of multiple sclerosis: review of their safety profile. Expert Opin Drug Saf. 2017;16(12):1359–1371.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: https://www.emdserono.com/us-en?global_redirect=1
   Google Scholar
• Martinelli Boneschi F, Vacchi L, Rovaris M, et al. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;31(5):Cd002127.DOI: 10.1002/14651858.CD002127.pub3.
   PubMed Web of Science ®Google Scholar
• Goodkin DE, Rudick RA, VanderBrug Medendorp S, et al. Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis. Ann Neurol. 1995;37(1):30–40.
   PubMed Web of Science ®Google Scholar
• Gray O, McDonnell GV, Forbes RB. Methotrexate for multiple sclerosis. Cochrane Database Syst Rev. 2004;(2):CD003208..
   Google Scholar
• Berger T, Elovaara I, Fredrikson S, et al. Alemtuzumab use in clinical practice: recommendations from european multiple sclerosis experts. CNS Drugs. 2017;31(1):33–50.
   PubMed Web of Science ®Google Scholar
• Baker DHS, Alvarez-Gonzalez C, Zalewski L, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360–e.
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW. et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Eng J Med. 2008;359(17):1786–1801.
   PubMed Web of Science ®Google Scholar
• Hartung HP, Aktas O, Boyko AN. Alemtuzumab: a new therapy for active relapsing-remitting multiple sclerosis. Mult Scler. 2015;21(1):22–34.
   PubMed Web of Science ®Google Scholar
• Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8(1):31–45.
   PubMed Web of Science ®Google Scholar
• Alroughani R, Singer BA, Broadley S, et al.Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study). Multiple Sclerosis and Related Disorders, Volume 26, 25
   Google Scholar
• Caon C, Namey M, Meyer C, et al. Prevention and management of infusion-associated reactions in the comparison of alemtuzumab and Rebif((R)) efficacy in multiple sclerosis (CARE-MS) program. Int J MS Care. 2015;17(4):191–198.
   PubMedGoogle Scholar
• Cuker A, Coles AJ, Sullivan H, et al. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis. Blood. 2011;118(24):6299.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: https://www.lemtradarems.com.
   Google Scholar
• Lorefice L, Fenu G, Gerevini S, et al. PML in a person with multiple sclerosis: is teriflunomide the felon?. Neurology. 2018;90(2):83–85.
   PubMed Web of Science ®Google Scholar
• Gerevini S, Capra R, Bertoli D, et al. Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy. Mult Scler. 2019 Jul;25(8):1196–1201.
   Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing
   Google Scholar
• McCall B. Alemtuzumab to be restricted pending review, says EMA. Lancet. 2019;393(10182):1683.
   PubMed Web of Science ®Google Scholar
• Azevedo CJ, Kutz C, Dix A, et al. Intracerebral haemorrhage during alemtuzumab administration. Lancet Neurol. 2019;18(4):329–331.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Cook S, Rammohan K, et al. Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol. 2011;10(4):329–337.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018;24(12):1594–1604.
   PubMed Web of Science ®Google Scholar
• Giovannoni G, Soelberg Sorensen P, Cook S, et al. Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. Mult Scler. 2019;25(6):819–827.
   PubMed Web of Science ®Google Scholar
• Leist TP, Comi G, Cree BA, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257–267.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: https://ichgcp.net/clinical-trials-registry/NCT00641537
   Google Scholar
• Schreiner TL, Miravalle A. Current and emerging therapies for the treatment of multiple sclerosis: focus on cladribine. J Cent Nerv Syst Dis. 2012;4:1–14.
   PubMedGoogle Scholar
• Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):416–426.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: http://dx.doi.org/10.1136/jnnp-2018-ABN.79
   Google Scholar
• [cited 2019 Jul]. Available from: https://www.ema.europa.eu/en/documents/product-information/mavenclad-epar-product-information_it.pdf
   Google Scholar
• Cohen JA, Baldassari LE, Atkins HL, et al. Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis: position statement from the American society for blood and marrow transplantation. Biol Blood Marrow Transplant. 2019;25(5):845–854.
   PubMed Web of Science ®Google Scholar
• Burt RK, Balabanov R, Han X, et al. Association of nonmyeloablative hematopoietic stem cell transplantation with neurological disability in patients with relapsing-remitting multiple sclerosis. Jama. 2015;313(3):275–284.
   PubMed Web of Science ®Google Scholar
• Reston JT, Uhl S, Treadwell JR, et al. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler. 2011;17(2):204–213.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Cottone S. Could autologous hematopoietic stem cell transplantation be considered a second-line treatment option in relapsing-remitting multiple sclerosis? A critical editorial. Expert Rev Precis Med Drug Dev. 2017;2(2):69–71.
   Web of Science ®Google Scholar
• D’Amico E, Patti F, Zanghì A, et al. A personalized approach in progressive multiple sclerosis: the current status of disease modifying therapies (DMTs) and future perspectives. Int J Mol Sci. 2016;17(10):1725.
   Web of Science ®Google Scholar
• Mancardi GL, Sormani MP, Gualandi F, et al. Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial. Neurology. 2015;84(10):981–988.
   PubMed Web of Science ®Google Scholar
• Atkins HL, Bowman M, Allan D, et al. Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet. 2016;388(10044):576–585.
   PubMed Web of Science ®Google Scholar
• Muraro PA, Pasquini M, Atkins HL, et al. Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol. 2017;74(4):459–469.
   PubMed Web of Science ®Google Scholar
• Sola-Valls N, Sepulveda M, Blanco Y, et al. Current role of chemotherapy and bone marrow transplantation in multiple sclerosis. Curr Treat Options Neurol. 2015;17(1):324.
   PubMed Web of Science ®Google Scholar
• Rice CM, Mallam EA, Whone AL, et al. Safety and feasibility of autologous bone marrow cellular therapy in relapsing-progressive multiple sclerosis. Clin Pharmacol Ther. 2010;87(6):679–685.
   PubMed Web of Science ®Google Scholar
• Brew BJ, Davies NW, Cinque P, et al. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–679.
   PubMed Web of Science ®Google Scholar
• Ho PR, Koendgen H, Campbell N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol. 2017;16(11):925–933.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghi A, Leone C, et al. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf. 2016;39(12):1163–1174.
   PubMed Web of Science ®Google Scholar
• Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–923.
   PubMed Web of Science ®Google Scholar
• Barbin L, Rousseau C, Jousset N, et al. Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study. Neurology. 2016;86(8):771–778.
   PubMed Web of Science ®Google Scholar
• Bargiela D, Bianchi MT, Westover MB, et al. Selection of first-line therapy in multiple sclerosis using risk-benefit decision analysis. Neurology. 2017;88(7):677–684.
   PubMed Web of Science ®Google Scholar
• Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev. 2015 Sep 18;(9):Cd011381.DOI: 10.1002/14651858.CD011381.pub2.
   Google Scholar
• Mills EA, Mao-Draayer Y. Understanding progressive multifocal leukoencephalopathy risk in multiple sclerosis patients treated with immunomodulatory therapies: a bird’s eye view. Front Immunol. 2018;9:138.
   PubMed Web of Science ®Google Scholar
• Mills EA, Mao-Draayer Y. Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. Mult Scler. 2018;24(8):1014–1022.
   PubMed Web of Science ®Google Scholar
• Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
   PubMed Web of Science ®Google Scholar
• Longbrake EE, Cross AH. Dimethyl fumarate associated lymphopenia in clinical practice. Mult Scler. 2015;21(6):796–797.
   PubMed Web of Science ®Google Scholar
• Nieuwkamp DJ, Murk JL, van Oosten BW, et al. PML in a patient without severe lymphocytopenia receiving dimethyl fumarate. N Engl J Med. 2015;372(15):1474–1476.
   PubMed Web of Science ®Google Scholar
• Rosenkranz T, Novas M, Terborg C. PML in a patient with lymphocytopenia treated with dimethyl fumarate. N Engl J Med. 2015;372(15):1476–1478.
   PubMed Web of Science ®Google Scholar
• van Oosten BW, Killestein J, Barkhof F, et al. PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med. 2013;368(17):1658–1659.
   PubMed Web of Science ®Google Scholar
• Bellizzi A, Nardis C, Anzivino E, et al. Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies. J Neurovirol. 2012;18(1):1–11.
   PubMed Web of Science ®Google Scholar
• Delgado-Alvarado M, Sedano MJ, Gonzalez-Quintanilla V, et al. Progressive multifocal leukoencephalopathy and idiopathic CD4 lymphocytopenia. J Neurol Sci. 2013;327(1–2):75–79.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: www.hrc.govt.nz/sites/default/files/CTCAE%20manual%20-%20DMCC.pdf
   Google Scholar
• Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124–1140.
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
   PubMed Web of Science ®Google Scholar
• Nakhaei-Nejad M, Barilla D, Lee C-H, et al. Characterization of lymphopenia in patients with MS treated with dimethyl fumarate and fingolimod. Neurol Neuroimmunol Neuroinflammation. 2018;5(2):e432.
   PubMed Web of Science ®Google Scholar
• Kapral M, Wawszczyk J, Sosnicki S, et al. Down-regulation of inducible nitric oxide synthase expression by inositol hexaphosphate in human colon cancer cells. Acta Poloniae Pharmaceutica. 2015;72(4):705–711.
   PubMed Web of Science ®Google Scholar
• Korn T, Magnus T, Toyka K, et al. Modulation of effector cell functions in experimental autoimmune encephalomyelitis by leflunomide–mechanisms independent of pyrimidine depletion. J Leukoc Biol. 2004;76(5):950–960.
   PubMed Web of Science ®Google Scholar
• Korn T, Toyka K, Hartung HP, et al. Suppression of experimental autoimmune neuritis by leflunomide. Brain. 2001;124(Pt 9):1791–1802.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Leone C, Caserta C, et al. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal. Expert Rev Neurother. 2015;15(7):803–824.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghì A, Gastaldi M, et al. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: present and future perspectives. Autoimmun Rev. 2019;18(7):665–672.
   PubMed Web of Science ®Google Scholar
• Mulero P, Midaglia L, Montalban X. Ocrelizumab: a new milestone in multiple sclerosis therapy. Ther Adv Neurol Disord. 2018;11:1756286418773025.
   Web of Science ®Google Scholar
• Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med. 2016;376(3):221–234.
   PubMed Web of Science ®Google Scholar
• D’Amico E, Zanghi A, Chisari CG, et al. Effectiveness and safety of Rituximab in demyelinating diseases spectrum: an Italian experience. Mult Scler Relat Disord. 2019;27:324–326.
   PubMed Web of Science ®Google Scholar
• Kowalec K, Kingwell E, Carruthers R, et al. Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case-control study protocol for dimethyl fumarate-induced lymphopenia. BMJ Open. 2017;7(5):e016276–e.
   PubMed Web of Science ®Google Scholar
• Pistono C, Osera C, Boiocchi C, et al. What’s new about oral treatments in multiple sclerosis? Immunogenetics still under question. Pharmacol Res. 2017;120:279–293.
   PubMed Web of Science ®Google Scholar
• Cotte S, von Ahsen N, Kruse N, et al. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain. 2009;132(Pt 9):2517–2530.
   PubMed Web of Science ®Google Scholar
• Grey S, Salmen A, von Ahsen N, et al. Lack of efficacy of mitoxantrone in primary progressive multiple sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis. J Neuroimmunol. 2015;278:277–279.
   PubMed Web of Science ®Google Scholar
• Alexoudi A, Zachaki S, Stavropoulou C, et al. Possible implication of GSTP1 and NQO1 polymorphisms on natalizumab response in multiple sclerosis. Ann Clin Lab Sci. 2016;46(6):586–591.
   PubMed Web of Science ®Google Scholar
• Samer CF, Lorenzini KI, Rollason V, et al. Applications of CYP450 testing in the clinical setting. Mol Diagn Ther. 2013;17(3):165–184.
   PubMed Web of Science ®Google Scholar
• [cited 2019 Jul]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/209884Orig1s000TOC.cfm
   Google Scholar
• Recommendations PotIoCCGotDDIPoSwPMACAfDL CPTIPD–D, Felix Huth AG, Ken‐Ichi Umehara, Handan He. [cited 2019 Jul]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/209884s000lbl.pdf.
   Google Scholar
• Harding K, Williams O, Willis M, et al. Clinical outcomes of escalation vs early intensive disease-modifying therapy in patients with multiple sclerosis. JAMA Neurol. 2019;76:536.
   PubMed Web of Science ®Google Scholar
• He A, Spelman T, Jokubaitis V, et al. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis. JAMA Neurol. 2015;72(4):405–413.
   PubMed Web of Science ®Google Scholar
• Giovannoni G. Personalized medicine in multiple sclerosis. Neurodegener Dis Manag. 2017;7(6s):13–17.
   PubMedGoogle Scholar
• Amato MP, Portaccio E, Goretti B, et al. Cognitive impairment in early stages of multiple sclerosis. Neurol Sci. 2010;31(2):211–214.
   Google Scholar
• Hawkins S. Truly benign multiple sclerosis is rare: let’s stop fooling ourselves – no. Mult Scler J. 2011;18(1):11–12.
   PubMed Web of Science ®Google Scholar
• Bonnet MC, Allard M, Dilharreguy B, et al. Cognitive compensation failure in multiple sclerosis. Neurology. 2010;75(14):1241–1248.
   PubMed Web of Science ®Google Scholar
• Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in multiple sclerosis. Front Neurol. 2015;6:82.
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology. 2010;74(24):2004–2015.
   PubMed Web of Science ®Google Scholar
• Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4(4):e360–e.
   PubMed Web of Science ®Google Scholar
• Schweitzer F, Laurent S, Fink GR, et al. Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis. Curr Opin Neurol. 2019;32(3):305–312.
   PubMed Web of Science ®Google Scholar